305 related articles for article (PubMed ID: 15806320)
21. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease.
Schäfer E; Baron K; Widmer U; Deegan P; Neumann HP; Sunder-Plassmann G; Johansson JO; Whybra C; Ries M; Pastores GM; Mehta A; Beck M; Gal A
Hum Mutat; 2005 Apr; 25(4):412. PubMed ID: 15776423
[TBL] [Abstract][Full Text] [Related]
22. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene.
Eng CM; Desnick RJ
Hum Mutat; 1994; 3(2):103-11. PubMed ID: 7911050
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel mutations in the α-galactosidase A gene in patients with Fabry disease: pitfalls of mutation analyses in patients with low α-galactosidase A activity.
Yoshimitsu M; Higuchi K; Miyata M; Devine S; Mattman A; Sirrs S; Medin JA; Tei C; Takenaka T
J Cardiol; 2011 May; 57(3):345-53. PubMed ID: 21333496
[TBL] [Abstract][Full Text] [Related]
24. Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P.
Fukutomi M; Tanaka N; Uchinoumi H; Kanemoto M; Nakao F; Yamada J; Kamei T; Takenaka T; Fujii T
J Cardiol; 2013 Jul; 62(1):63-9. PubMed ID: 23608164
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease. Mutations in brief no. 169. Online.
Chen CH; Shyu PW; Wu SJ; Sheu SS; Desnick RJ; Hsiao KJ
Hum Mutat; 1998; 11(4):328-30. PubMed ID: 9554750
[TBL] [Abstract][Full Text] [Related]
26. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes.
Nowak A; Mechtler TP; Desnick RJ; Kasper DC
Mol Genet Metab; 2017; 120(1-2):57-61. PubMed ID: 27773586
[TBL] [Abstract][Full Text] [Related]
27. Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease.
Topaloglu AK; Ashley GA; Tong B; Shabbeer J; Astrin KH; Eng CM; Desnick RJ
Mol Med; 1999 Dec; 5(12):806-11. PubMed ID: 10666480
[TBL] [Abstract][Full Text] [Related]
28. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey.
Schaefer E; Mehta A; Gal A
Acta Paediatr Suppl; 2005 Mar; 94(447):87-92; discussion 79. PubMed ID: 15895718
[TBL] [Abstract][Full Text] [Related]
29. [Molecular genetics of inherited metabolic diseases--its application to the investigation of pathogenesis and the diagnosis of Fabry disease].
Sakuraba H
Rinsho Byori; 1994 Jun; 42(6):628-35. PubMed ID: 7914243
[TBL] [Abstract][Full Text] [Related]
30. Heterozygote detection in Fabry disease utilizing multiple enzyme activities.
Sheth KJ; Good TA; Murphy JV
Am J Med Genet; 1981; 10(2):141-6. PubMed ID: 6274191
[TBL] [Abstract][Full Text] [Related]
31. A novel mutation of α-galactosidase A gene causes Fabry disease mimicking primary erythromelalgia in a Chinese family.
Ge W; Wei B; Zhu H; Miao Z; Zhang W; Leng C; Li J; Zhang D; Sun M; Xu X
Int J Neurosci; 2017 May; 127(5):448-453. PubMed ID: 27211852
[TBL] [Abstract][Full Text] [Related]
32. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.
Rombach SM; Dekker N; Bouwman MG; Linthorst GE; Zwinderman AH; Wijburg FA; Kuiper S; Vd Bergh Weerman MA; Groener JE; Poorthuis BJ; Hollak CE; Aerts JM
Biochim Biophys Acta; 2010 Sep; 1802(9):741-8. PubMed ID: 20471476
[TBL] [Abstract][Full Text] [Related]
33. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches.
Germain DP; Poenaru L
Biochem Biophys Res Commun; 1999 Apr; 257(3):708-13. PubMed ID: 10208848
[TBL] [Abstract][Full Text] [Related]
34. Detection of large gene rearrangements in X-linked genes by dosage analysis: identification of novel α-galactosidase A (GLA) deletions causing Fabry disease.
Dobrovolny R; Nazarenko I; Kim J; Doheny D; Desnick RJ
Hum Mutat; 2011 Jun; 32(6):688-95. PubMed ID: 21305660
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the alpha galactosidase gene: mutation profile and description of two novel mutations with extensive literature review in Turkish population.
Onay H; Bolat H; Kılıç Yıldırım G; Kose E; Kalkan Uçar S; Aşıkovalı S; Özkınay F; Çoker M
J Pediatr Endocrinol Metab; 2020 Aug; 33(10):1245-1250. PubMed ID: 32813676
[TBL] [Abstract][Full Text] [Related]
36. The D313Y variant in the GLA gene - no evidence of a pathogenic role in Fabry disease.
Hasholt L; Ballegaard M; Bundgaard H; Christiansen M; Law I; Lund AM; Norremolle A; Krogh Rasmussen A; Ravn K; Tumer Z; Wibrand F; Feldt-Rasmussen U
Scand J Clin Lab Invest; 2017 Dec; 77(8):617-621. PubMed ID: 29037082
[TBL] [Abstract][Full Text] [Related]
37. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns.
Lee BH; Heo SH; Kim GH; Park JY; Kim WS; Kang DH; Choe KH; Kim WH; Yang SH; Yoo HW
J Hum Genet; 2010 Aug; 55(8):512-7. PubMed ID: 20505683
[TBL] [Abstract][Full Text] [Related]
38. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography.
Shabbeer J; Robinson M; Desnick RJ
Hum Mutat; 2005 Mar; 25(3):299-305. PubMed ID: 15712228
[TBL] [Abstract][Full Text] [Related]
39. Identification of GLA gene deletions in Fabry patients by Multiplex Ligation-dependent Probe Amplification (MLPA).
Schirinzi A; Centra M; Prattichizzo C; Gigante M; De Fabritiis M; Giancaspro V; Petrarulo F; Santacroce R; Margaglione M; Gesualdo L; Ranieri E
Mol Genet Metab; 2008 Jul; 94(3):382-5. PubMed ID: 18472290
[TBL] [Abstract][Full Text] [Related]
40. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.
Wang RY; Lelis A; Mirocha J; Wilcox WR
Genet Med; 2007 Jan; 9(1):34-45. PubMed ID: 17224688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
